Glenmark Receives EMA Approval for Olanzapine Generic, Olazax, Entering Schizophrenia and Bipolar Disorder Markets
Product Overview and Approval Pathway
Olazax is a generic version of the atypical antipsychotic olanzapine. Glenmark Pharmaceuticals s.r.o. received marketing authorization (EMEA/H/C/001087) from the EMA on December 11, 2009. Through the Generic Authorisation Pathway, approval was granted by demonstrating bioequivalence to the original brand, Zyprexa (Eli Lilly). This allowed Glenmark to secure EU-wide sales rights without independent clinical trial data. It is classified as a dibenzodiazepine atypical antipsychotic with ATC code N05AH03 and is currently in revision version 13.
Indications and Formulation
Olazax is approved for three indications: treatment and maintenance therapy for schizophrenia in adults, treatment of moderate to severe manic episodes, and prevention of relapse of manic episodes in patients with bipolar disorder. The mechanism of action of olanzapine involves dual serotonin (5-HT) and dopamine (D2) receptor blockade, leading to improved PANSS (Positive and Negative Syndrome Scale) scores. Efficacy is based on data established in clinical trials of the original Zyprexa. The formulation consists of standard oral tablets of 5mg, 7.5mg, 10mg, 15mg, and 20mg. The recommended starting dose for schizophrenia is 10mg/day, and for manic episodes, it is 15mg/day. Dose reduction is recommended for patients with hepatic or renal impairment and the elderly.
Competitive Landscape and Original Market Status
The original brand of olanzapine, Zyprexa, was a key blockbuster for Eli Lilly and was the top-selling antipsychotic in the EU. Competing drugs with the same indications include risperidone (Janssen), quetiapine (Seroquel, AstraZeneca), and aripiprazole (Abilify, Otsuka/BMS). Olanzapine faced increasing pressure for prescription diversification compared to newer atypical antipsychotics such as aripiprazole, due to its metabolic side effects (weight gain, abnormal fasting blood glucose).
Glenmark's EU Entry Strategy
Glenmark Pharmaceuticals (NSE: GLENMARK) is an India-based global generic pharmaceutical company that entered the EU antipsychotic generic market through its EU subsidiary, Glenmark Pharmaceuticals s.r.o. (Czech Republic). Olazax, in standard oral tablet form, aims to benefit from the INN (International Nonproprietary Name) prescription mandate policies of national health services such as the NHS and GKV, by offering a lower price compared to the original brand. However, in Germany, in 2009, the Federal Court of Justice upheld Eli Lilly's Zyprexa patent, leading to the withdrawal of generics from the market. This highlights that patent disputes in individual countries can be a key factor limiting actual market penetration for generic companies.
EU Schizophrenia Treatment Market Size
The EU antipsychotic market was dominated by second-generation antipsychotics (SGAs) in the late 2000s, reaching a size of several billion euros. The global prevalence of schizophrenia is approximately 1% of the population, with the EU having several million patients. Due to the chronic nature of the disease, it represents a long-term prescription market. The entry of olanzapine generics put downward pressure on prices across the category and squeezed the margins of the original Zyprexa. This led Eli Lilly to shift its revenue portfolio to subsequent pipelines such as Cymbalta (duloxetine).
The approval of Olazax represents a case where the entry of olanzapine generics into the EU market was accelerated after the expiration of Eli Lilly's Zyprexa patent, leading to lower prices and increased patient access across the EU antipsychotic market. Glenmark maximized its prescription base by obtaining approval for three indications (schizophrenia and bipolar disorder) and aimed to penetrate the market by utilizing the INN prescription mandate policies of the NHS and GKV. The precedent set in Germany in 2009, where Eli Lilly successfully re-established its patent and forced the withdrawal of generics, demonstrates the structural risk that differences in patent environments across the EU pose to the revenue predictability of generic pharmaceutical companies. During this period, the emergence of alternative atypical antipsychotics such as quetiapine (AstraZeneca) and aripiprazole (Otsuka/BMS), combined with the metabolic side effect issues of olanzapine, limited the growth of the category even after the entry of generics. From the perspective of those preparing for careers in the pharmaceutical industry, this serves as a practical example to understand the EU generic approval pathway (utilizing BE data), multi-indication strategies, and barriers to entry into national insurance coverage.
Source: EMA (ema)